CERo Therapeutics (CERO) Insider Trading & Ownership $0.19 -0.02 (-9.65%) (As of 11/14/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends CERo Therapeutics (NASDAQ:CERO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage18.00%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$325,000.00 Get CERO Insider Trade Alerts Want to know when executives and insiders are buying or selling CERo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CERO Insider Buying and Selling by Quarter Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. CERo Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/10/2024Bioventures Opportunities G YkMajor ShareholderSell3,250,000$0.10$325,000.00 (Data available from 1/1/2013 forward) CERO Insider Trading Activity - Frequently Asked Questions Who is on CERo Therapeutics's Insider Roster? The list of insiders at CERo Therapeutics includes Bioventures Opportunities G Yk. Learn more on insiders at CERO. What percentage of CERo Therapeutics stock is owned by insiders? 18.00% of CERo Therapeutics stock is owned by insiders. Learn more on CERO's insider holdings. Which CERo Therapeutics insiders have been selling company stock? The following insider sold CERO shares in the last 24 months: Bioventures Opportunities G Yk ($325,000.00). How much insider selling is happening at CERo Therapeutics? Insiders have sold a total of 3,250,000 CERo Therapeutics shares in the last 24 months for a total of $325,000.00 sold. CERo Therapeutics Key ExecutivesDr. Daniel Mark Corey M.D. (Age 45)Founder, CTO & Director Compensation: $372.69kMr. Brian G. Atwood (Age 71)President, CEO & Chairman Mr. Charles Ross Carter (Age 56)CFO, Treasurer & Corporate Secretary Dr. Robert Sikorski M.D. (Age 61)Ph.D., Consultant More Insider Trading Tools from MarketBeat Related Companies DURECT Insider Transactions Rallybio Insider Transactions Lantern Pharma Insider Transactions vTv Therapeutics Insider Transactions Clene Insider Transactions Elevation Oncology Insider Transactions OKYO Pharma Insider Transactions Passage Bio Insider Transactions Verrica Pharmaceuticals Insider Transactions Lexaria Bioscience Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:CERO) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | SponsoredTrump Win = "Bull Trap"?Dan's research shows that the last time the market looked this way, not only did our economy suffer a large su...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
